Precision Analytic Research Methods in OCD
Dissecting Neurocognitive Components of Compulsivity Using Computational Modeling and EEG
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Amy Rapp, Ph.D.
- Phone Number: 212-241-5288
- Email: OCDResearch@mssm.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Principal Investigator:
- Amy Rapp
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants must be:
- between the ages 18-55 years old
- English-speaking
- right-handed
- able to provide consent
Exclusion Criteria:
Individuals diagnosed with OCD will be excluded if:
- they meet diagnostic criteria for certain other psychiatric disorders
- are taking psychiatric medication or have received behavioral treatment for OCD within a certain timeframe
- if it is unsafe for them to participate in research
Healthy control participants will be excluded if:
- they have a current psychiatric disorder
- a lifetime history of certain psychiatric disorders
- are taking psychiatric medication or have in the past
- have a parent or sibling who has been diagnosed with OCD
- if it is unsafe for them to participate in research
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Participants diagnosed with OCD
All participants diagnosed with Obsessive Compulsive Disorder (OCD) who enroll in this study will receive 17 sessions of exposure and response prevention, a specialized cognitive behavioral therapy for OCD, over the course of 10 weeks.
|
Exposure and response prevention (EX/RP) is the gold-standard behavioral treatment for OCD.
It involves confronting the content of obsessions (distressing thoughts, images, or impulses) and resisting the urge to engage in compulsions (observable behaviors or mental acts that are repeated to reduce the anxiety/distress associated with compulsions).
|
|
No Intervention: Healthy controls
Individuals who do not have a current or lifetime psychiatric diagnosis will not receive any treatment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: Week 1, Week 5, Week 10
|
A semi-structured clinician-administered instrument used to measure obsessions and compulsions separately over five dimensions (time consumed, distress, interference, degree of resistance, control).
The range of scores for the Obsessions and Compulsions subscales is 0-20, and the range for the total score is 0-40.
Higher scores indicate greater symptom severity, and a total score greater or equal to 16 is considered indicative of moderately severe OCD
|
Week 1, Week 5, Week 10
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Obsessive Compulsive Inventory- Revised
Time Frame: Week 1, Week 5, Week 10
|
An 18-item self-report measure to assess obsessions and compulsions that demonstrates good psychometric properties and has been used in other research as a transdiagnostic measure of compulsivity.
The range of scores for the six subscales (Washing; Obsessing; Ordering; Checking; Neutralizing; Hoarding) is 0-12.
The range for the total score is 0-60 and does not include the Hoarding subscale.
Higher scores indicate greater symptom severity.
|
Week 1, Week 5, Week 10
|
|
Cambridge-Chicago Compulsivity Trait Scale
Time Frame: Week 1, Week 5, Week 10
|
A 15-item self-report measure to assess compulsivity transdiagnostically that exhibits high internal consistency and excellent convergent validity with gold-standard measures of compulsive symptoms.
The range for the total score is 0-45, with higher scores indicating greater symptom severity
|
Week 1, Week 5, Week 10
|
|
Self-Report Habit Index
Time Frame: Week 1, Week 5, Week 10
|
A 12-item self-report measure of the repetition and automaticity of a behavior that exhibits high internal consistency and test-retest reliability.
The range for the total score is 12-84, with higher scores indicating greater symptom severity.
|
Week 1, Week 5, Week 10
|
|
Dimensional Obsessive- Compulsive Scale
Time Frame: Week 1, Week 5, Week 10
|
A 20-item self-report measure that assesses four of the most consistently replicated thematic dimensions of OCD symptoms (i.e., contamination, harm, symmetry, repugnant content).
The DOCS demonstrates good to excellent internal consistency, validity, and sensitivity.
The range of scores for the four subscales (Contamination; Harm; Unacceptable Thoughts; Symmetry) is 0-20, and the range for the total score is 0-80.
Higher scores indicate greater symptom severity.
|
Week 1, Week 5, Week 10
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Amy Rapp, PhD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY-24-01125
- K23MH133997 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.